Clinical trial
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal…
NCT00110929 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00110929 |
|---|---|
| Title | Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) |
| Official title | A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | End Stage Renal Disease |
| Intervention type | Drug |
| Interventions | AMG 073 |
| Enrollment | 850 |
| Start date | Nov 1, 2002 |
| First posted | May 17, 2005 |
| Last update posted | Apr 23, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: